Iohexol versus metrizamide for cervical myelography: double-blind trial.
Cervical myelography was performed by lateral C1-C2 puncture in 60 patients. Thirty patients received iohexol (an investigational aqueous contrast agent) and 30 received metrizamide in order to provide a prospective, randomized, double-blind trial comparing these contrast media. The two media produced radiographs of equal quality. Contrast-related morbidity was suffered by four patients (13%) in the iohexol group and by 11 patients (37%) in the metrizamide group. These features indicate that iohexol is superior to metrizamide as a contrast agent for cervical myelography.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D007472:Iohexol; D008297:Male; D008793:Metrizamide / Q000009:adverse effects; D008875:Middle Aged; D009192:Myelography / Q000379:methods*; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D008793:Metrizamide